Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HJB647
- Development stage
- Phase 1
- Lead developer
- Novartis
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
HJB647 is an investigational oral compound being developed by Novartis for the treatment of chronic heart failure. It is currently in early-stage clinical development, specifically targeting patients with heart failure with reduced ejection fraction (HFrEF) and heart failure with mildly reduced ejection fraction (HFmrEF). As of late 2023, the drug is undergoing Phase 1 clinical evaluation (NCT06143319) to investigate its safety, tolerability, and pharmacokinetics in participants with chronic stable heart failure. While the specific biological target and mechanism of action have not been publicly disclosed by Novartis, its formulation as a capsule for oral administration suggests it is a small molecule candidate.
Beyond the preview
Go deeper on HJB647.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HJB647.